Kodiak Sciences Inc. 是一家临床阶段生物制药公司,致力于在美国及国际市场研究、开发和推广用于治疗视网膜疾病的疗法。公司总部位于加利福尼亚州帕洛阿尔托。
财务指标
营业收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
营业支出
2026-06-30
$6683.8万
2026-03-31
$5977.7万
2025-12-31
$5745.3万
2025-09-30
$6235.2万
净利润
2026-06-30
-$6564.3万
2026-03-31
-$5815.8万
2025-12-31
-$5673.6万
2025-09-30
-$6145.7万
净利润率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-1.05
2026-03-31
$-0.94
2025-12-31
$-1.04
2025-09-30
$-1.16
息税折旧摊销前利润
2026-06-30
-$6059万
2026-03-31
-$5181.8万
2025-12-31
-$4651.7万
2025-09-30
-$5491.8万
有效税率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$0
$0
$0
$0
营业支出
$6683.8万
$5977.7万
$5745.3万
$6235.2万
净利润
-$6564.3万
-$5815.8万
-$5673.6万
-$6145.7万
净利润率
--
--
--
--
每股收益
$-1.05
$-0.94
$-1.04
$-1.16
息税折旧摊销前利润
-$6059万
-$5181.8万
-$4651.7万
-$5491.8万
有效税率
--
--
--
--
常见问题
KOD represents the common stock of Eastman Kodak Company, a company historically known for photographic film and imaging products. In recent years, Kodak has diversified into commercial printing, advanced materials, and chemical manufacturing, including pharmaceutical ingredients. Its operations serve both commercial and industrial customers, and the company has shifted focus toward higher-margin technology and chemical businesses while maintaining its traditional imaging segment. Revenue is generated through product sales and services across several geographic regions, with a significant portion coming from the United States and Europe.
Recent performance for KOD can vary significantly due to its small-cap nature, low share price, and sensitivity to news. The stock has historically experienced periods of high volatility, often driven by announcements related to restructuring, financing, or new business initiatives. To see the latest price changes, trading volume, and percentage moves, check the real-time performance data displayed on this KOD stock page. That information reflects current market conditions and is more reliable than any static summary.
The 52-week range for KOD is the lowest and highest price at which the stock has traded over the past year. This metric helps investors gauge the stock's volatility and current position relative to its annual trading history. Since the 52-week range changes daily with market activity, the most accurate and up-to-date figures are available in the price and performance section of this page. Reviewing that range alongside recent price action provides context for how KOD has been valued by the market.
Valuation for KOD can be assessed using metrics such as price-to-sales, price-to-book, and enterprise value-to-EBITDA, since earnings-based measures like the P/E ratio may be less reliable when profits are inconsistent. Comparing these multiples with industry peers and the company's own historical averages provides context. Because KOD operates in varied segments, a sum-of-the-parts approach may also be useful. The latest valuation ratios and market data are listed in the valuation section of this page.
KOD carries risks common to small-cap and turnaround-oriented companies, including volatile share prices, limited analyst coverage, and sensitivity to financing conditions. Its businesses face competitive pressures in imaging, printing, and chemicals, and past restructuring efforts have led to uneven financial results. Liquidity risk may also apply if trading volumes are low. Additionally, exposure to economic cycles, raw material costs, and regulatory changes can affect operations. Investors should review risk factors in the company's SEC filings for a comprehensive view.
Key metrics for KOD include revenue growth, gross margin, operating cash flow, and debt levels. Because the company has historically reported volatile earnings, cash flow and balance sheet strength are particularly relevant. Investors may also track segment performance across its imaging, printing, and advanced materials businesses. Comparing these metrics over multiple quarters can reveal trends. The latest financial statements and ratios are available in the financials section of this page, providing a data-driven basis for research.